Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
NCT ID: NCT00348634
Last Updated: 2016-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
60 participants
INTERVENTIONAL
2006-07-31
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
NCT00365820
Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation
NCT00153140
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
NCT00414024
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
NCT00171522
The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia
NCT00277550
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tegaserod
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must meet the criteria for chronic idiopathic constipation for at least 12 weeks
* Patients must have had a colonoscopy within the past 5 years
* Patients must pass a balloon expulsion test at screening
* Patients must be able to comply and understand the use of a diary
Exclusion Criteria
* Patients with loose stools at least once per week
* Patients with IBS
* Known allergies to the same class of drug and/or allergies to eggs
* Patients who require the use of manual maneuvers to have a bowel movement
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Temple University
OTHER
University of Michigan
OTHER
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Henry Parkman, MD
Role: STUDY_CHAIR
Temple
William Chey, MD
Role: STUDY_CHAIR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arkansas Gastroenterology, PA
North Little Rock, Arizona, United States
University of Michigan Medical Center
Ann Arbor, Michigan, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHTF919EUS51
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.